Press release from Companies
Publicerat: 2022-04-19 17:30:00
Cessatech A/S ("Cessatech" or the "Company") today releases its results for the period 1 January – 31 March 2022. The first quarter report is available as an attached document to this press release and on www.cessatech.com under Investor/Filings & Reports. The company is progressing with planned activities: Recruitment of trial 0206 is nearly complete (a trial to investigate the pharmacokinetics in children aged 1-17 undergoing elective surgical procedures) and we are currently finalising the preparation for the initiation of our pivotal trial with CT001 (0205). We anticipate trial 0205 to start recruitment during Q2 2022.
First quarter 2021 (1 January - 31 March): *Earnings per share (DKK per share): Operating result divided by the average number of shares during the period. The total number of shares as of 31 March 2022 amounted to 6.112.535 shares, the average number of shares during the first quarter was 6.112.353 Highlights during first quarter 2022 “During the first quarter of 2022 we have nearly finalised the recruitment in our Phase 2 (0206) pharmacokinetic study with CT001, and importantly we announced Topline results of clinical trial 0204 investigating the absolute bioavailability of CT001 showed clinical relevant exposures following nasal administration. We are still pending formal approval of trial 0205 from regulatory authorities and we expect to start this study during Q2. We have been off to a good start of 2022 and anticipate a very exciting year for the Company.“ says Jes Trygved, CEO For more information about Cessatech, please contact: About Cessatech
There has been an increase in the number of shares in Q4 2021 related to the exercise of warrant TO 1.
**Solidity: Total equity divided by total capital and liability.
Jes Trygved, CEO
Phone: +45 9387 2309
E-mail: jes.trygved@cessatech.com
www.cessatech.com
Cessatech A/S is a Danish pharmaceutical company committed to developing and commercialising evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, being easy to administer, a fast-acting therapeutic effect, and being medically approved for children. CT001 is at its pivotal stage of clinical development.
